Business Context and Reporting Period
Company: Fractyl Health, Inc. (Nasdaq: GUTS)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: Fractyl is a clinical-stage metabolic therapeutics company developing disease-modifying therapies for obesity and Type 2 Diabetes (T2D). Its lead product, Revita, is an endoscopic device for duodenal mucosal resurfacing. Its second platform, Rejuva, is a pancreatic gene therapy platform.
Strategic Reprioritization: In January 2025, the company announced a strategic shift to prioritize the REMAIN-1 pivotal study for Revita (weight maintenance after GLP-1 discontinuation). Consequently, investment in the REVITALIZE-1 study (Revita for T2D) and the Germany Real-World Registry was paused. This included a workforce reduction of 22 employees (approx. 17%).
Key Financial Metrics
| Metric (in thousands) | 2025 | 2024 |
|---|---|---|
| Revenue | $0 | $93 |
| Net Loss | $(140,954) | $(68,694) |
| Research & Development Expenses | $74,536 | $70,471 |
| Selling, General & Administrative Expenses | $22,280 | $23,103 |
| Cash and Cash Equivalents (Dec 31, 2025) | $81,540 | $67,464 |
| Accumulated Deficit | $(556,264) | $(415,310) |
| Notes Payable (Long-term) | $30,586 | $30,162 |
Liquidity: As of December 31, 2025, the company held $81.5 million in cash. Management estimates this, combined with $4.1 million in subsequent warrant exercise proceeds received in January 2026, will fund operations into early 2027.
Material Changes vs. Prior Period
- Revenue Cessation: Revenue dropped to zero in 2025 from $93,000 in 2024 due to the pause in the commercial pilot launch in Germany as part of the Strategic Reprioritization.
- Net Loss Expansion: Net loss more than doubled to $141.0 million from $68.7 million. This was primarily driven by a $40.9 million non-cash loss from the change in fair value of warrant liabilities and a $4.7 million loss from the change in fair value of notes payable.
- Financing Activity: The company raised significant capital in 2025 through an August offering ($22.6 million net), a September offering ($56.0 million net), an ATM offering ($6.8 million net), and warrant exercises ($19.7 million net).
- Going Concern: The company has identified conditions raising substantial doubt about its ability to continue as a going concern, citing the need for additional capital to meet liquidity covenants on its 2023 Notes by the end of 2026.
Guidance, Outlook, and Risks
Clinical and Regulatory Outlook
- Revita (REMAIN-1 Study): Enrollment for the Pivotal Cohort (n=315) was completed in July 2025, with randomization finished in February 2026. Topline 6-month data is expected in early Q4 2026. A potential De Novo marketing application submission is targeted for late Q4 2026.
- Rejuva (RJVA-001): Clinical Trial Applications (CTAs) were submitted to regulators in the EU and Australia in late 2025. First-in-human dosing is expected in H2 2026, subject to authorization.
Key Risks and Contingencies
- Capital Requirements: The company requires substantial additional capital to execute its operating plan. Failure to raise funds could force delays or elimination of development programs.
- Debt Covenants: The company must maintain a minimum liquidity covenant of $10.0 million under its Credit Agreement. Without additional financing, compliance by the end of 2026 is uncertain.
- Regulatory Uncertainty: There is no guarantee that the FDA will grant De Novo classification for Revita or that Rejuva will receive regulatory approval. Safety events could lead to reclassification to Class III (requiring a PMA).
- Stock Price Compliance: In March 2026, the company received notice from Nasdaq regarding non-compliance with the minimum bid price requirement ($1.00), granting 180 days to regain compliance.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $81.5 million cash balance to fund operations through early 2027 and meet the $10 million liquidity covenant on the 2023 Notes.
- REMAIN-1 Data Readout: Monitor the anticipated Q4 2026 topline data for the REMAIN-1 Pivotal Cohort, which is critical for the De Novo submission.
- Financing Needs: Assess the likelihood and terms of future equity or debt financing required to bridge the gap beyond early 2027.
- Nasdaq Compliance: Track the company's progress in regaining compliance with the Nasdaq minimum bid price requirement by September 9, 2026.
- Warrant Liability Volatility: Note that a significant portion of the 2025 net loss was non-cash (fair value adjustments); future stock price volatility will continue to impact reported earnings.